Source of cannabinoids: what is available, what is used, and where does it come from?

Epileptic Disord 2020 Jan;22(S1):1-9

UCL-Institute of Child Health, Great Ormond Street Hospital for Children, Member of the European Reference Network EpiCARE, London & Young Epilepsy, Lingfield, UK.

Cannabis sativa L. is an ancient medicinal plant wherefrom over 120 cannabinoids are extracted. In the past two decades, there has been increasing interest in the therapeutic potential of cannabis-based treatments for neurological disorders such as epilepsy, and there is now evidence for the medical use of cannabis and its effectiveness for a wide range of diseases. Cannabinoid treatments for pain and spasticity in patients with multiple sclerosis (Nabiximols) have been approved in several countries. Cannabidiol (CBD), in contrast to tetra-hydro-cannabidiol (THC), is not a controlled substance in the European Union, and over the years there has been increasing use of CBD-enriched extracts and pure CBD for seizure disorders, particularly in children. No analytical controls are mandatory for CBD-based products and a pronounced variability in CBD concentrations in commercialized CBD oil preparations has been identified. Randomized controlled trials of plant-derived CBD for treatment of Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) have provided evidence of anti-seizure effects, and in June 2018, CBD was approved by the Food and Drug Administration as an add-on antiepileptic drug for patients two years of age and older with LGS or DS. Medical cannabis, with various ratios of CBD and THC and in different galenic preparations, is licensed in many European countries for several indications, and in July 2019, the European Medicines Agency also granted marketing authorisation for CBD in association with clobazam, for the treatment of seizures associated with LGS or DS. The purpose of this article is to review the availability of cannabis-based products and cannabinoid-based medicines, together with current regulations regarding indications in Europe (as of July 2019). The lack of approval by the central agencies, as well as social and political influences, have led to significant variation in usage between countries.

Download full-text PDF

Source
http://dx.doi.org/10.1684/epd.2019.1121DOI Listing
January 2020

Similar Publications

Cannabinoids in treatment-resistant epilepsy: A review.

Epilepsy Behav 2017 05 8;70(Pt B):341-348. Epub 2017 Feb 8.

NYU Epilepsy Center, New York, NY, United States. Electronic address:

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered placebo-controlled, randomized trials (RCTs) with cannabidiol (CBD), a cannabis derivative. Previously, information was limited to case reports, small series, and surveys reporting on the use of CBD and diverse medical marijuana (MMJ) preparations containing: tetrahydrocannabinol (THC), CBD, and many other cannabinoids in differing combinations. Read More

View Article and Full-Text PDF
May 2017

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Epilepsia 2014 Jun 22;55(6):791-802. Epub 2014 May 22.

Department of Neurology, Comprehensive Epilepsy Center, New York University School of Medicine, New York, New York, U.S.A.

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. Read More

View Article and Full-Text PDF
June 2014

Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.

Epilepsy Behav 2015 Jun 29;47:138-41. Epub 2015 Apr 29.

Division of Pediatric Neurology, Mattel Children's Hospital at UCLA, David Geffen School of Medicine, Los Angeles, CA, USA.

There is a great need for safe and effective therapies for treatment of infantile spasms (IS) and Lennox-Gastaut syndrome (LGS). Based on anecdotal reports and limited experience in an open-label trial, cannabidiol (CBD) has received tremendous attention as a potential treatment for pediatric epilepsy, especially Dravet syndrome. However, there is scant evidence of specific utility for treatment of IS and LGS. Read More

View Article and Full-Text PDF
June 2015

Cannabis for the Treatment of Epilepsy: an Update.

Curr Neurol Neurosci Rep 2018 09 8;18(11):73. Epub 2018 Sep 8.

Department of Neurology, University of Alabama at Birmingham Epilepsy Center, Birmingham, AL, USA.

Purpose Of Review: For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy. Read More

View Article and Full-Text PDF
September 2018